Jones Financial Companies Lllp Has $326,000 Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Jones Financial Companies Lllp grew its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 38.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 9,338 shares of the company’s stock after purchasing an additional 2,614 shares during the period. Jones Financial Companies Lllp’s holdings in Ionis Pharmaceuticals were worth $326,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of IONS. Baker BROS. Advisors LP acquired a new stake in Ionis Pharmaceuticals in the third quarter valued at approximately $8,952,000. Geode Capital Management LLC lifted its stake in shares of Ionis Pharmaceuticals by 7.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,668,358 shares of the company’s stock valued at $106,922,000 after acquiring an additional 183,814 shares during the last quarter. Sovran Advisors LLC acquired a new stake in shares of Ionis Pharmaceuticals during the 4th quarter valued at $5,617,000. Assenagon Asset Management S.A. boosted its holdings in shares of Ionis Pharmaceuticals by 967.2% during the 4th quarter. Assenagon Asset Management S.A. now owns 141,917 shares of the company’s stock valued at $4,961,000 after acquiring an additional 128,619 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Ionis Pharmaceuticals by 8.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,443,020 shares of the company’s stock worth $57,807,000 after acquiring an additional 114,914 shares during the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, Director Michael R. Hayden purchased 5,000 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was acquired at an average cost of $36.22 per share, with a total value of $181,100.00. Following the completion of the acquisition, the director now directly owns 35,219 shares of the company’s stock, valued at $1,275,632.18. This represents a 16.55 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Eric Swayze sold 7,154 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $32.84, for a total value of $234,937.36. Following the transaction, the executive vice president now owns 45,670 shares of the company’s stock, valued at $1,499,802.80. The trade was a 13.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 111,816 shares of company stock worth $3,603,914. Corporate insiders own 2.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IONS. StockNews.com downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 12th. William Blair restated an “outperform” rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Piper Sandler lowered their target price on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. JPMorgan Chase & Co. decreased their target price on Ionis Pharmaceuticals from $51.00 to $47.00 and set a “neutral” rating for the company in a research report on Tuesday. Finally, Citigroup reduced their price objective on Ionis Pharmaceuticals from $67.00 to $64.00 and set a “buy” rating for the company in a report on Thursday, February 20th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Ionis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $59.56.

Ionis Pharmaceuticals Stock Up 2.5 %

IONS stock opened at $33.03 on Wednesday. The company has a fifty day moving average of $32.85 and a 200-day moving average of $37.12. The stock has a market capitalization of $5.25 billion, a PE ratio of -10.87 and a beta of 0.28. The company has a debt-to-equity ratio of 2.12, a quick ratio of 8.82 and a current ratio of 8.47. Ionis Pharmaceuticals, Inc. has a one year low of $30.23 and a one year high of $52.34.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Wednesday, February 19th. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.46. The firm had revenue of $227.00 million for the quarter, compared to analysts’ expectations of $140.97 million. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The firm’s revenue for the quarter was down 30.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.12 earnings per share. As a group, analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current year.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.